Drug Profile
Quetmolimab - EA Pharma/Eisai Co Ltd
Alternative Names: E-6011; KANAb 001Latest Information Update: 20 May 2022
Price :
$50
*
At a glance
- Originator KAN Research Institute
- Developer EA Pharma; Eisai Co Ltd
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Chemokine CX3CL1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
- Discontinued Primary biliary cirrhosis; Rheumatoid arthritis
Most Recent Events
- 20 May 2022 Discontinued - Phase-II for Crohn's disease in Czech Republic, Hungary, Poland, Japan (IV), due to business priorities (EA Pharma, Eisai Co Ltd pipeline, May 2022)
- 04 Aug 2021 Discontinued - Phase-II for Rheumatoid arthritis (Adjunctive treatment) in Japan, prior to August 2021 (SC)
- 06 Oct 2020 Eisai enters into a joint research agreement with KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, Yokohama City University to develop therapeutics to prevent COVID-2019 infections